47 results
424B5
MRK
Merck & Co Inc
10 May 23
Prospectus supplement for primary offering
4:27pm
and life-cycle management, and is expected over time to develop research capabilities in selected therapeutic areas. The Spin-Off is expected
424B5
MRK
Merck & Co Inc
8 May 23
Prospectus supplement for primary offering
8:17am
to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management
424B5
pe2gwpufj 6718
9 Dec 21
Prospectus supplement for primary offering
4:37pm
424B5
8gal03l7x2kvpe
7 Dec 21
Prospectus supplement for primary offering
8:13am
S-3ASR
tenj0
25 Mar 21
Automatic shelf registration
4:46pm
S-3ASR
91o k3v8j4sna01bj
25 Mar 21
Automatic shelf registration
4:42pm
424B5
1jqf5oo01e0k08rrjbb
18 Jun 20
Prospectus supplement for primary offering
4:59pm
424B5
vrx 3t1rzz5eam90h54
16 Jun 20
Prospectus supplement for primary offering
9:04am